1. Medtech Insight
  3. >>Neurology

Investors Lay $5m On Savonix's Vision To Make Cognitive Data 'Cheap, Fast, Easy' To Access

 
• By Marion Webb

Savonix has raised $5.1m to further advance its mobile app-based cognitive assessment tool used by clinicians to help develop their patients' treatment plan. The company's founder and CEO, Mylea Charvat, said the 30-minute assessment is faster and much more cost-effective than conventional paper and pen testing, and opens the door for better outcomes for patients who otherwise wouldn't have access to cognitive testing.

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.

San Francisco-based Savonix, which has developed an evidence-based cognitive assessment mobile app designed to replace conventional pen and paper testing, has raised a further $5.1m in Series A funding. This brings the total investment received by the company to date to $6.6m.

Savonix CEO Mylea Charvat told Medtech Insight she plans to use the latest financing to build out the firm's back-end...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

 
• By Marion Webb, Brian Bossetta, Natasha Barrow, Elizabeth Orr, and Shubham Singh

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from Device Area